| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | ARDAN PHARMA S.A.S. | AVENIDA BELGRANO 758 | SUNCHALES | SANTA FE | | | ARG | R21CA263424 | Characterization of an inflammasome-unleashing approach to improve anti-PD-1 therapy in cancer | 000 | 2 | NIH | 4/8/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $120,219 ) |
| | 2022 | 2022 | ARDAN PHARMA S.A.S. | AVENIDA CORDOBA 1776, PISO 4 | CIUDAD DE BUENOS AIRES | | | | ARG | R21CA263424 | Characterization of an inflammasome-unleashing approach to improve anti-PD-1 therapy in cancer | 000 | 2 | NIH | 9/13/2022 | $120,219 |
|
| Issue Date FY: 2021 ( Subtotal = $155,024 ) |
| | 2021 | 2021 | ARDAN PHARMA S.A.S. | AVENIDA CORDOBA 1776, PISO 4 | CIUDAD DE BUENOS AIRES | | | | ARG | R21CA263424 | Characterization of an inflammasome-unleashing approach to improve anti-PD-1 therapy in cancer | 000 | 1 | NIH | 8/23/2021 | $155,024 |
|
|
